In Table 1 in the original version of this article (1), the value in row “Ex19ins” and column “Pooled RDE” should be “1 (2).” Table 1 has been corrected in the latest online HTML and PDF versions of the article. The authors regret the error.
Reference
1.
Jänne
PA
,
Baik
C
,
Su
WC
,
Johnson
ML
,
Hayashi
H
,
Nishio
M
, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor–resistant, EGFR-mutated non–small cell lung cancer
. Cancer Discov
2022
;12
:74
–89
.©2022 The Authors; Published by the American Association for Cancer Research
2022
American Association for Cancer Research
This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.
RSS Feeds